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Processing of the transmembrane glycoprotein (GP) of Marburg virus involved the conversion of an endo H-sensitive,
ER-specific form into an endo H-resistant, Golgi-specific precursor that was cleaved into GP1 and GP2. Cleavage was
mediated by furin or another subtilisin-like endoprotease with similar substrate specificity as indicated by mutational analysis
of the cleavage site and inhibition using peptidyl chloromethylketones. Mature GP consisted of disulfide-linked GP1 and GP2
subunits. © 2000 Academic Press
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sIntroduction. Marburg virus (MBGV) and Ebola virus
(EBOV), the two species within the family Filoviridae, are
among the most pathogenic agents causing fulminant
hemorrhagic fever in humans and nonhuman primates
(10, 32). The genomes of both filoviruses display linear
rranged genes on a single negative-stranded RNA mol-
cule that encodes the seven structural proteins in the
rder nucleoprotein, virion structural protein (VP) 35,
P40, glycoprotein (GP), VP30, VP24, and RNA-depen-
ent RNA polymerase (L) (9). In contrast to EBOV that
equires transcriptional editing to express the transmem-
rane GP (34, 37, 38), the GP gene of MBGV is organized
n a way that transcription results in a single subgenomic
NA species used for the synthesis of the full-length
nvelope glycoprotein (43). Thus, MBGV does not ex-
ress the nonstructural small glycoprotein sGP that is
ynthesized from the nonedited mRNA species during
BOV infection and secreted into the culture medium (34,
8, 40).
MBGV and EBOV GP are trimeric type I transmem-
rane proteins (5, 12, 35, 39). They are heavily N- and
-glycosylated primarily in the variable, extremely hydro-
hilic middle region of the molecules (11, 12, 17, 43).
ecently, first experimental data have been published
egarding GP functions. The transmembrane GP of EBOV
ediates targeting to susceptible cells (36, 44, 46), and
1 To whom correspondence and reprint requests may be addressed.
. E. Volchkov, fax: 149-6421.288962. E-mail: volchkov@mailer.uni-mar-
urg.de. H. Feldmann (present address), Canadian Science Centre for
uman and Animal Health, 1015 Arlington Street, Winnipeg, Manitobaw
p
3E 3R2, Canada. Fax: (204) 789-2140. E-mail: Heinz_Feldmann@hc-
c.gc.ca.
1he asialoglycoprotein receptor has been postulated as a
eceptor candidate for MBGV on hepatocytes (2). GP
urther carries a putative fusion domain as indicated by
omputer-assisted sequence analysis (15). Recently Ito
t al. (22), using a vesicular stomatitis virus expression
ystem, have demonstrated that mutations in this domain
odify the ability of EBOV GP to support infectivity.
Many viral surface glycoproteins undergo posttransla-
ional proteolytic processing. Most of these glycopro-
eins are cleaved by subtilisin-like eukaryotic endopro-
eases (proprotein convertases) at multibasic cleavage
ites (16, 26, 27). In previous reports on MBGV GP such
cleavage process was not described (1, 14, 43). How-
ver, this type of processing has recently been demon-
trated with EBOV GP that is cleaved at the sequence
-T-R-R501 into the disulfide-linked fragments GP1 and
GP2 (35, 39). The present study has therefore, been
ocused on proteolytic processing in order to either iden-
ify such a process during maturation of MBGV GP as
ell or verify another distinction between the two spe-
ies within the family Filoviridae.
Results and Discussion. Analysis of the amino acid
equence of MBGV GP showed the presence of two
ultibasic motifs, R-R-K-R435 and R-L-R-R561, which are
otential cleavage sites of furin or related proprotein
onvertases (Fig. 1A). In order to investigate if GP under-
oes proteolytic cleavage during maturation, synthesis
f GP was analyzed by pulse–chase labeling experi-
ents using the vaccinia virus-T7 polymerase expres-
ion system (Fig. 2A). HeLa cells (3 3 106) were infected
ith a recombinant vaccinia virus expressing T7 RNA
olymerase (vTF7-3), and subsequently transfected with
0042-6822/00 $35.00
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2 RAPID COMMUNICATIONthe plasmid coding for MBGV GP, strain Musoke. SDS–
PAGE analysis under reducing conditions showed that
GP was processed into two GP-specific polypeptide
bands, GP1 (;160 kDa) and GP2 (;38 kDa). GP ap-
eared first as a common precursor of about 140 kDa
preGPer) that had previously been identified as the en-
oplasmic reticulum precursor due to its endo H sensi-
ivity (1). Later in chase, preGPer was converted into a
igher molecular mass precursor preGP, which then was
ffectively processed into the subunits GP1 and GP2. It
was difficult to distinguish preGP and GP1 in pulse-chase
experiments due to extensive glycosylation of both pro-
teins and the short life period of the Golgi precursor
preGP. However, increasing amounts of GP2 observed
uring the chase periods clearly demonstrated the pro-
eolytic processing. The cleavage of GP was abolished
hen GP was expressed in the presence of the decanoy-
ated peptidyl chloromethylketone decRVKR-cmk (Fig.
A), a potent inhibitor of the subtilisin-like endoprotease
urin (16). Under these conditions predominantly non-
leaved preGP was synthesized which clearly showed a
igher molecular mass than GP1. These data support the
concept of proteolytic processing of MBGV GP mediated
by furin or another endoprotease of similar substrate
specificity. SDS–PAGE analysis under nonreducing con-
FIG. 1. Schematic illustration of Marburg virus GP. (A) Primary stru
-linked carbohydrate side chains are indicated by asterisks (*) and cy
contains the fusion peptide (526–540), followed by an amino-terminal he
Helices were proposed by the GARNIER program of PC/GENE (Intell
indicated as boxes, and two amphipathic helices as cylinders. (C) Com
known filoviruses.ditions showed that GP1 and GP2 are complexed, most
likely by a cysteine–cysteine bond, as indicated by thepresence of a single band designated as GP1,2 (Fig. 2B).
As has been observed with EBOV (40), MBGV GP was
also found in culture medium (Fig. 2C, left). Analysis
under nonreducing conditions showed that the released
GP represented the soluble GP1 subunit (Fig. 2C, right).
Shedding of GP1 is most likely due to the release of the
isulfide linkage to membrane-anchored GP2 during pro-
ein processing. A similar event has also been observed
ith the HA1 subunit of the influenza hemagglutinin (33).
Since MBGV GP is processed into two subunits, only
one of two putative cleavage sites is recognized. Cleav-
age at position 561 seemed to be very unlikely because
the molecular mass of GP2 (;38 kDa) estimated by
SDS–PAGE was significantly higher than expected for a
protein consisting of 120 amino acids with only two
potential N-linked glycosylation sites. In order to further
support the notion that cleavage occurs at position 435
(R24-R23-K22-R21) we exchanged amino acids at position
21 (R435L; R-R-K-L) and 22 (K434M; R-R-M-R) using site-
irected mutagenesis. Wild-type GP and mutants R435L
and K434M were transiently expressed in HeLa cells. After
pulse labeling for 20 min with [35S]cysteine and chase
incubation for 4 h, GP-specific proteins were immuno-
precipitated with a monoclonal antibody. Substitution of
Arg435 (R435L) resulted in complete loss of cleavage, indi-
howing the co- and posttranslational modifications of GP1,2. Potential
residues by “C.” (B) Proposed structure of GP2. The ectodomain of GP2
–594), a peptide loop (602–609), and a carboxy-terminal helix (613–632).
cs Inc.). The putative fusion peptide and transmembrane anchor are
of the conserved furin-like motifs in the envelope glycoproteins of allcture s
steine
lix (553
iGeneticating that GP indeed is cleaved at R-R-K-R435 (Fig. 3).
Mutation at position 22 (K434M) showed a reduction in
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3RAPID COMMUNICATIONcleavage efficiency demonstrated by the presence of
uncleaved GP and both cleavage products. Thus, the
cleavage site of MBGV GP shows the typical features of
the consensus sequence recognized by furin or the re-
lated proprotein convertase PC5/6, which contains Arg at
positions 21 and 24 as a minimal requirement and
rg/Lys at position 22 for cleavage optimization (31).
nvolvement of furin or other furin-like cellular endopro-
eases in the process of cleavage of EBOV GP has been
ecently confirmed by Wool-Lewis and Bates (45). How-
ver, these authors, unlike our observations, did not
xclude involvement of other proteases in the process-
ng of EBOV GP. Data obtained now with MBGV GP
FIG. 2. Transport and proteolytic processing of Marburg virus glyco-
rotein GP. HeLa cells were infected with vTF7-3, and transfected with
plasmid carrying the entire coding region of MBGV GP (strain Mu-
oke). Proteins were pulse labeled for 20 min with 100 mCi/ml [35S]cys-
eine and chased for the indicated time intervals. GP-specific proteins
ere immunoprecipitated from cell lysates and culture medium with
uinea pig anti-MBGV immunoglobulins and analyzed on 10% SDS–
AGE under reducing (A, B, and C) and nonreducing conditions (B and
). (B and C) HeLa cells were infected with vTF7-3, transfected with
lasmid DNA, metabolically pulse labeled, and chased for 240 min. The
resence of the decanoylated peptidyl chloromethylketone decRVKR (25
nd 60 mM) during labeling and chase abolished cleavage of preGP.onfirmed our previous observation made on EBOV GP
39) and clearly demonstrated a requirement of a furin
i
tleavage site for proteolytic processing of filoviral GPs.
his is further supported by the recently determined
mino-terminal end of the EBOV transmembrane GP2
(35).
It is interesting to note, that basic di- or tripeptides
(R-R, R-K, K-R, R-K-R, or R-R-K) are either part of the
furin-like cleavage site or located in the close vicinity in
all filoviral GPs (Fig. 1C). The role of these basic paired
residues in cleavage of filoviral GP is not clear yet.
Theoretically, they could also be recognized by other
cellular proprotein endoproteases and, therefore, be in-
volved in cleavage of GP. Data on other viral glycopro-
teins, such as influenza HA and the F protein of
paramyxoviruses, indicate that cleavage can occur at
single basic residues (R or K) present in the cleavage
sites (24–27). In these particular cases, proteins are only
cleaved after arrival of viruses at the cell surface (18, 19)
or even during endocytosis by yet unidentified endoso-
mal endoproteases (3). The role of basic paired residues
in cleavage has been well documented for the HA of
avian influenza viruses and the F protein of Newcastle
disease virus. Here, the differences in pathogenicity
clearly correlate with the cleavability of these proteins
(25). The GPC proteins of some arenaviruses, such as
lymphocytic choriomeningitis virus, Lassa virus, and
Pichinde virus, also contain dibasic sequences at the
FIG. 3. Site-directed mutagenesis at the cleavage site. The mutants
R435L and K434M were generated by PCR mutagenesis using the Quick-
change kit (Stratagene). HeLa cells were infected with vTF7-3, trans-
fected with plasmid DNA, metabolically pulse labeled for 30 min with
100 mCi/ml [35S]cysteine, and chased for 240 min. GP-specific proteins
ere immunoprecipitated from cell lysates with a GP-specific mono-
lonal antibody (II9G4) and analyzed on 10% SDS–PAGE under reduc-ng conditions. The sequences at the cleavage sites are shown at the
op.
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4 RAPID COMMUNICATIONproposed proteolytic cleavage site that might be cleaved
by plasmin or another serum protease recognizing such
cleavage sites (4, 26, 27). In the case of MBGV and EBOV
GP (39), cleavage was almost entirely abolished after
mutation of the Arg at position 21 of the cleavage site,
although one dibasic motif was still present. Thus, non-
furin-like cellular endoproteases do not seem to play any
role in the process of proteolytic maturation of filoviral
GP. For EBOV subtype Reston, in which the furin-like
cleavage motif is altered at position 24 (Lys instead of
Arg), a reduced cleavability of GP has recently been
demonstrated (39). In contrast to all other EBOV, subtype
Reston seems to be low or apathogenic for humans and
seems to possess lower pathogenicity for nonhuman
primates as well (13). Therefore, it is tempting to specu-
late that cleavability may also determine filoviral patho-
genicity.
In order to verify if virion GP of MBGV also consists of
two cleavage products, Vero-E6 cells were inoculated
with MBGV, strain Musoke, and metabolically labeled for
24 h on day 5 postinfection prior to virus harvest. Label-
ing with [3H]fucose or [3H]glycosamine revealed, as ex-
ected, two glycoproteins, a larger one of approximately
60 kDa and a smaller, weakly labeled one of approxi-
ately 38 kDa (Fig. 4). Both proteins were sensitive to
reatment with PNGase F (Fig. 4, right), indicating the
resence of N-linked carbohydrates on both subunits.
In conclusion, the data presented here demonstrate
hat MBGV GP is proteolytically processed during its
aturation by a subtilisin-like cellular endoprotease.
roteolytic cleavage is an important control mechanism
f the biological activity of many viral surface proteins
nd occurs often next to a hydrophobic domain involved
n fusion (21, 26, 27). GP2 of MBGV and EBOV (15, 28, 41)
ave some structural features typical for viral fusion
FIG. 4. Identification of the proteolytic subunits of Marburg virus
lycoprotein (GP). MBGV, strain Musoke, was grown on Vero cells and
abeled for 24 h with different 3H sugars (100 mCi/ml) at day 5 postin-
fection. Virus particles were harvested and proteins were analyzed on
10% SDS–PAGE (reducing conditions) prior to or after treatment with
endoglycosidase PNGase F (Boehringer Mannheim, Germany). *GP1,
GP1 after removal of N-linked carbohydrates.roteins. They include a potential fusion peptide down-
tream of the cleavage site and two amphipathic helices
C
shat are separated by a loop formed by a disulfide bond
Fig. 1B). Such structures have been observed with the
ransmembrane subunits HA2 of the influenza virus hem-
agglutinin (6, 7), gp41 of the HIV env protein (8, 42), and
F1 of the paramyxovirus fusion protein (23). Since all of
these proteins require cleavage and conformational
changes for fusion, it is reasonable to assume that
MBGV GP also undergoes proteolytic activation. Taking
into consideration a strong structural similarity between
filovirus GPs and other viral fusion proteins and a high
conservation of the cleavage site among all filoviruses, it
is tempting to speculate that proteolytic cleavage is an
important factor for the pantropism of filoviruses and
their rapid spread through the organism. Recent studies
using murine leukemia virions pseudotyped with EBOV
GP suggested that proteolytic cleavage was not abso-
lutely necessary for viral infectivity (45). However, as
already mentioned by the authors, their one-step infec-
tion assay may not be sufficient to address the impor-
tance of cleavage during multiple cycles of virus replica-
tion in an infected host. Furthermore, it cannot be ex-
cluded that GP in those pseudotyped particles may have
become activated during adsorption or endosomal up-
take as discussed above. Further studies are needed to
clarify the importance of cleavage in filoviral infectivity
and pathogenicity. Recent reports describing the devel-
opment of minigenome techniques for both filoviruses
(29, 30) will allow us to establish reverse genetic sys-
tems that may shed light into the molecular mechanisms
of filovirus pathogenicity in the near future.
Materials and Methods. Viruses and cell cultures.
Strain Musoke of MBGV was propagated on Vero-E6
cells (ATCC CRL 1586) and purified from tissue culture
medium as described previously (12). The recombinant
vaccinia viruses vTF7-3 expressing T7 polymerase (pro-
vided by B. Moss, NIH, MD) was propagated in CV-1
cells. CV-1, HeLa, and Vero-E6 cells were maintained in
Dulbecco’s modified Eagle’s medium (GIBCO, Germany)
containing 10% FCS (GIBCO).
Pulse–Chase Experiments. HeLa cells (3 3 106) were
infected with vTF7-3 at a m.o.i. of 10 pfu/cell. The inoc-
ulum was replaced after 1 h by transfection medium
containing plasmid DNA [9 mg; 15 ml lipofectin (BRL,
ermany)]. Cells were washed 6 h postinfection, starved
n cysteine-free medium for 1 h, and labeled with 100
mCi/ml [35S]cysteine (Amersham, Germany). After a 20-
in pulse, the inoculum was replaced with medium for a
hase. Labeled cells were lysed immediately in Co-IP
uffer [1% Nonidet P-40 (NP-40), 0.4% sodium deoxy-
holate, 0.5% BSA, 5 mM EDTA, 100 mM NaCl, 20 mM
ris–HCl, pH 7.6, 25 mM iodoacetamide, 1 mM PMSF] at
°C. Immunoprecipitation was performed using guinea
ig anti-MBGV immunoglobulins (kindly provided by A. A.
hepurnov, Institute of Molecular Biology, Koltsovo, Rus-
ia) or with a MBGV GP monoclonal antibody [II9G4,
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5RAPID COMMUNICATIONkindly provided by M. Hevey and A. Schmaljohn, U.S.
Army Medical Research Institute of Infectious Diseases,
Fort Detrick, MD (20)]. Precipitated proteins were visual-
ized by fluorography or quantified with the Fuji BAS 1000
bio-imaging analyzer (Raytest, Germany).
Metabolic Labeling. Vero-E6 cells (75 cm2 flasks) were
inoculated with MBGV, strain Musoke, at an m.o.i. of 1
pfu/cell for 1 h. Cells were washed 5 days postinfection
with Dulbecco’s medium, starved in glucose-free me-
dium for 1 h, and metabolically labeled with 500 mCi/ml
[3H]glucosamine or [3H]fucose (Amersham). The virus
as harvested 24 h postlabeling and partially purified
rom culture medium by centrifugation through a 20%
ucrose cushion (120 min at 100,000g). The pelleted virus
as resuspended in PBS and lysed with 2% SDS, 1%
P-40, and 0.4% deoxycholate. Viral proteins were sub-
ected to 10% SDS–PAGE under reducing conditions and
isualized by fluorography.
Endoproteolytic Cleavage Inhibition Assay. For cleav-
ge inhibition studies, HeLa cells infected with vTF7-3,
nd subsequently transfected with a plasmid carrying
he entire coding region of MBGV GP (strain Musoke),
ere incubated during starvation, pulse, and chase pe-
iods either without or with the decanoylated peptidyl
hloromethylketone (decRVKR-cmk) at concentrations of
5 or 60 mM. Immunoprecipitation analyses were carried
out as described previously (39).
Site Directed Mutagenesis. Construction of the plas-
mid which directs synthesis of the wild-type MBGV GP
was described earlier (43). In order to generate the
cleavage site mutants of GP (R435L and K434M), PCR
mutagenesis was performed using the Quick-change kit
(Stratagene, Germany). All clones were verified by se-
quence determination.
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